About: Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
AVDL NASDAQ Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals PLC share price
Atividade de preço de AVDL
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
AVDL price performance
quote.marketSignals